Form 4: iTeos Therapeutics CEO Transfers Stock Options to Belgian Partnership
SEC Form 4
CEO of iTeos Therapeutics, Michel Detheux, transferred stock options to MG3A, a Belgian partnership.
Summary
- Michel Detheux, CEO of iTeos Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- On August 8, 2024, Detheux transferred stock options, representing the right to buy 442,800 shares of common stock at $11.58, to MG3A, a Belgian partnership.
- Detheux is the manager of MG3A, and his spouse is the successor manager.
- Following the transaction, Detheux directly owns 147,600 stock options and indirectly owns 442,800 stock options through MG3A.
- The transferred stock options vest over four years, with 25% vesting on March 7, 2025, and the remainder vesting in equal monthly installments over the subsequent 36 months, contingent upon Detheux's continued service to iTeos Therapeutics.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a transfer of stock options, which could be for estate planning or tax purposes.
Stakeholder Impact
- The transfer of stock options could have a minor impact on shareholders, as it changes the beneficial ownership structure.
Key Dates
| Date | Description |
|---|---|
| 08/08/2024 | Date of stock option transfer to MG3A |
| 03/07/2025 | First vesting date for 25% of the transferred stock options |
| 03/07/2034 | Expiration date of the stock options |
| 08/09/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.